The Biomarkers for Identifying Preclinical Alzheimer's Disease via Structural and Functional Magnetic Resonance Imaging

Yanhong Zhou, Chuangchuang Tan, Dong Wen, Hongmin Sun, Wei Han, Yuchen Xu, Yanhong Zhou, Chuangchuang Tan, Dong Wen, Hongmin Sun, Wei Han, Yuchen Xu

No abstract available

Keywords: cognitive reserve; functional magnetic resonance imaging; gene; mild cognitive impairment; preclinical Alzheimer's disease; protein; structural magnetic resonance imaging.

References

    1. Besson F. L., La Joie R., Doeuvre L., Gaubert M., Mézenge F., Egret S., et al. . (2015). Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. J. Neurosci. 35, 10402–10411. 10.1523/JNEUROSCI.0150-15.2015
    1. Brier M. R., Thomas J. B., Fagan A. M., Hassenstab J., Holtzman D. M., Benzinger T. L., et al. . (2014). Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiol. Aging 35, 757–768. 10.1016/j.neurobiolaging.2013.10.081
    1. Doraiswamy P. M., Sperling R. A., Coleman R. E., Johnson K. A., Reiman E. M., Davis M. D., et al. . (2012). Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline A multicenter study. Neurology 79, 1636–1644. 10.1212/WNL.0b013e3182661f74
    1. Drzezga A., Becker J. A., Van Dijk K. R. A., Sreenivasan A., Talukdar T., Sullivan C., et al. . (2011). Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 134, 1635–1646. 10.1093/brain/awr066
    1. Duara R., Loewenstein D. A., Potter E., Barker W., Raj A., Schoenberg M., et al. . (2011). Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am. J. Geriatric Psychiatry 19, 951–960. 10.1097/JGP.0b013e3182107c69
    1. Erk S., Meyer-Lindenberg A., von Boberfeld C. O., Esslinger C., Schnell K., Kirsch P., et al. . (2011). Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. J. Neurosci. 31, 18180–18184. 10.1523/JNEUROSCI.4960-11.2011
    1. Ferencz B., Karlsson S., Kalpouzos G. (2012). Promising genetic biomarkers of preclinical Alzheimer's disease: the influence of APOE and TOMM40 on brain integrity. Int. J. Alzheimers Dis. 2012, 421–452. 10.1155/2012/421452
    1. Gordon B. A., Zacks J. M., Blazey T., Benzinger T. L. S., Morris J. C., Fagan A. M., et al. . (2015). Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. Neurobiol. Aging 36, 1771–1779. 10.1016/j.neurobiolaging.2015.01.019
    1. Green A. E., Gray J. R., DeYoung C. G., Mhyre T. R., Padilla R., DiBattista A. M., et al. . (2014). A combined effect of two Alzheimer's risk genes on medial temporal activity during executive attention in young adults. Neuropsychologia 56, 1–8. 10.1016/j.neuropsychologia.2013.12.020
    1. Harrison T. M., Burggren A. C., Small G. W., Bookheimer S. Y. (2016). Altered memory-related functional connectivity of the anterior and posterior hippocampus in older adults at increased genetic risk for Alzheimer's disease. Hum. Brain Mapp. 37, 366–380. 10.1002/hbm.23036
    1. Harrison T. M., Bookheimer S. Y. (2016). Neuroimaging genetic risk for Alzheimer's disease in preclinical individuals: from candidate genes to polygenic approaches. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 1, 14–23. 10.1016/j.bpsc.2015.09.003
    1. Miller M. I., Younes L., Ratnanather J. T., Brown T., Trinh H., Postell E., et al. . (2013). The diffeomorphometry of temporal lobe structures in preclinical Alzheimer's disease. Neuroimage Clin. 3, 352–360. 10.1016/j.nicl.2013.09.001
    1. Miller M. I., Ratnanather J. T., Tward D. J., Brown T., Lee D. S., Ketcha M., et al. . (2015). Network neurodegeneration in Alzheimer's disease via MRI based shape diffeomorphometry and high-field atlasing. Front. Bioeng. Biotechnol. 3, 1–16. 10.3389/fbioe.2015.00054
    1. Moghekar A., Li S., Lu Y., Li M., Wang M.-C., Albert M., et al. . (2013). CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 81, 1753–1758. 10.1212/01.wnl.0000435558.98447.17
    1. Sepulcre J., Liu H., Talukdar T., Martincorena I., Yeo B. T. T., Buckner R. L. (2010). The organization of local and distant functional connectivity in the human brain. PLoS Comput. Biol. 6:e1000808. 10.1371/journal.pcbi.1000808
    1. Sheline Y. I., Raichle M. E., Snyder A. Z., Morris J. C., Head D., Wang S., et al. . (2010). Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol. Psychiatry 67, 584–587. 10.1016/j.biopsych.2009.08.024
    1. Soldan A., Pettigrew C., Lu Y., Wang M.-C., Selnes O., Albert M., et al. . (2015). Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. Hum. Brain Mapp. 36, 2826–2841. 10.1002/hbm.22810
    1. Sperling R. A., Aisen P. S., Beckett L. A., Bennett D. A., Craft S., Fagan A. M., et al. . (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280–292. 10.1016/j.jalz.2011.03.003
    1. Wang Y., Risacher S. L., West J. D., McDonald B. C., MaGee T. R., Farlow M. R., et al. . (2013). Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J. Alzheimers Dis. 35, 751–760. 10.3233/JAD-130080
    1. Younes L., Albert M., Miller M. I., BIOCARD Research Team . (2014). Inferring changepoint times of medial temporal lobe morphometric change in preclinical Alzheimer's disease. Neuroimage Clin. 5, 178–187. 10.1016/j.nicl.2014.04.009

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit